Author:
Lu Meng-Yao,Wang Ning,Wu Wen-Hsin,Lai Cheng-Wei,Kuo Pei-Hsin,Chiang Po-Hung,Lin Kai-Hsin,Wu Tzu-Hua
Subject
Pharmacology (medical),Pharmacology
Reference24 articles.
1. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias;Cappellini;Haematologica,2010
2. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions;Neufeld;Blood,2006
3. Pharmacokinetics, metabolism, and disposition of deferasirox in β-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state;Waldmeier;Drug Metabolism and Disposition,2010
4. A new HPLC UV validated method for therapeutic monitoring of deferasirox in thalassaemic patients;De Francia;J Chromatogr B Analyt Technol Biomed Life Sci,2012
5. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia;Galanello;J Clin Pharmacol,2003
Cited by
23 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献